Verada
← Group
Launching January 2027

Verada Rehab Clinics

Someone has to go first.

Rehabilitation technology that works abroad does not fail in the UK on the science. It fails because no clinic will buy what no clinic has run, and no commissioner will fund what has never been costed here. We break that loop by going first, at our own commercial risk, and publishing what we find.

Where Are You?

Technologies enter at the stage they are actually at

The evidence you can collect depends entirely on where a technology sits, and some of it cannot be collected later at any price. There is no single entry point, and no requirement to choose only one.

Still in trials Randomisation, a clean baseline and a blinded assessment can only be captured while the study is running. Design the evidence you will need in 2031 into the protocol you are writing now. Clinical Research →
Approved, not adopted Utilisation, staffing, cost per session and payback can only be produced by an organisation actually running the service, in the health system you are trying to enter. You are here
Both, in sequence Enter in trials and continue through approval into routine care. Same instrumentation, same population, same data layer, and one unbroken record from first baseline to a commissioning decision. The reason both exist
The Problem

Approval is where the hard part starts

A CE or FDA mark says a technology is safe and performs as intended. It says nothing a clinic director actually needs to know before committing capital and clinical time.

Clinical evidence answers a question the buyer has already stopped asking. The evidence that unlocks a purchase is operational and economic, and only an operator can produce it.

A manufacturer cannot generate it, because they do not run clinics. A registry cannot, because it collects outcomes rather than operations. An academic centre cannot credibly, because its cost base and staffing do not resemble a commercial clinic's. That leaves a gap that only a real service, run at real cost, can fill.

What We Do

Deliver the care. Publish the proof.

We adopt technology already proven in other health systems and put it in front of UK patients, under qualified clinical supervision, before anyone else is willing to. Everything else follows from doing that one thing properly.

1

Treat patients

Structured, protocolised rehabilitation for neurological, musculoskeletal and cognitive conditions, delivered by trained clinicians against defined selection criteria. This is the service, and it is what patients pay for.

2

Instrument everything

Repetitions, intensity against each patient's own calibrated maximum, session duration, adherence, pre- and post-session symptom ratings. Recorded as a by-product of care rather than as a separate research burden.

3

Publish what it costs

Utilisation, throughput, therapist grade, training time, completion and dropout, cost and revenue per session, payback period. The numbers a clinic director needs and nobody currently publishes.

Three Layers Of Evidence

Not all evidence answers the same question

"Real-world evidence" is usually taken to mean clinical outcomes. That is one third of what a technology needs to reach scale, and it is the third that is already best served.

Clinical
Does it work here, in our population? Outcome measures, durability, safety signals, and the post-market clinical follow-up manufacturers are legally obliged to generate. Answers the regulator.
Operational
Can a normal clinic actually run it? Throughput per device, staffing model, training burden, workflow fit, utilisation over time, completion and dropout rates. Answers the clinic director.
Economic
Does it pay? Cost per session, revenue or tariff per session, payback period, and budget impact modelled the way a commissioner models it. Answers the payor.
Who It's For

Two relationships, one service

For patients & families

Access to treatment that exists, but not here yet

Technology routinely available in other health systems, delivered under qualified clinical supervision, with honest information about who it suits and who it does not.

  • Clear eligibility assessed before you commit, not after
  • Realistic expectations: ranges rather than promises
  • Structured programmes with progress measured objectively each session
  • Qualified clinicians working to defined protocols
Self-pay at launch, with insurer and commissioned routes to follow as the evidence base develops.
For device manufacturers

You have the mark. You don't have UK scale.

We become your first UK site at our own commercial risk, and turn going first into a package that lets the clinics after us go second.

  • A named reference site treating real patients under a registered provider
  • Operational proof: utilisation, throughput, therapist grade, training time, dropout
  • Economic proof: cost and revenue per session, payback period, budget impact
  • A deployment blueprint: protocols, selection criteria, SOPs, training curriculum
  • Clinicians who take a peer's phone call and say what it was actually like
Post-market clinical follow-up is a standing regulatory obligation, not discretionary spend. We would rather it produced something commercially useful.
The Commitment

We publish the numbers we would rather not

The whole proposition rests on being a credible reference. A site that only ever reports flattering figures is a marketing exercise, and buyers work that out quickly.

If utilisation runs at sixty per cent rather than eighty-five, we publish sixty. That is what makes eighty-five believable when we get there.

The same principle applies to outcomes. Where a technology does not deliver what was expected in our population, we say so, including for technologies we hold commercial relationships with. Independence that has never cost anything is not independence.

Where We Are

Honest status

Service launch
Targeting January 2027. First patients will be treated in partnership with an established CQC-registered provider while Verada's own registration is progressed.
First indication
Upper-limb rehabilitation after stroke. A defined beachhead with a well-characterised population, clear outcome measures, and a large group of people whose NHS therapy has ended while recovery has not.
Technology
Partner technologies proven in other health systems. Availability in each territory depends on the regulatory approvals in force there at the time, and differs between the UK and the United States.
Clinical governance
Delivery under a registered provider, led by a clinical director in rehabilitation and occupational therapy, with patient selection against defined criteria and documented exclusions.
Geography
United Kingdom first, with a parallel United States service planned through a licensed partner practice. Different regulatory positions apply in each.
The Rest Of The Group

What sits alongside

The clinic is the asset the rest of Verada runs on. The same trained staff, the same instrumentation and the same data layer serve two further functions.

Bring us a technology

If you manufacture rehabilitation technology that works elsewhere and stalls in the UK, or you are a clinician who wants to refer, we would like to hear from you.

Start a conversation
About this division. Verada Rehab Clinics is a trading division of Verada Health Ltd, registered in England & Wales under company number 17137766. It is not currently a separate legal entity. Verada Health Ltd intends to incorporate its divisions as separate companies within the Verada group as each reaches operational scale. Nothing on this page is medical advice, an offer of treatment, or an offer or invitation to invest, and statements about future plans, timelines and regulatory outcomes are targets rather than commitments. See our Terms of Use.